Connect with us

Technology

Dolby Laboratories Reports First Quarter 2025 Financial Results

Published

on

SAN FRANCISCO, Jan. 29, 2025 /PRNewswire/ — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the first quarter of fiscal 2025.

“We are off to a strong start for FY25,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “In Q1, Dolby Atmos and Dolby Vision momentum continued across device categories. At CES, many of our device partners announced a wide range of Dolby enabled products, and customers experienced the first Dolby Vision enabled car with Li Auto.”

First Quarter Fiscal 2025 Financial Highlights

Total revenue was $357 million, compared to $316 million for the first quarter of fiscal 2024.GAAP net income was $68 million or $0.70 per diluted share, compared to GAAP net income of $67 million or $0.69 per diluted share for the first quarter of fiscal 2024. On a non-GAAP basis, first quarter net income was $111 million or $1.14 per diluted share, compared to $99 million or $1.01 per diluted share for the first quarter of fiscal 2024.Dolby repurchased approximately 186,000 shares of its common stock for approximately $15 million, and ended the quarter with approximately $387 million of stock repurchase authorization available going forward.

A complete listing of Dolby’s non-GAAP measures are described and reconciled to the corresponding GAAP measures at the end of this release.

Recent Business Highlights

At CES, our partners announced a wide range of new products incorporating Dolby technologies, including:Soundbar announcements from Harmon Kardon, Samsung, and Amazon all support Dolby technology.TV launches from partners including Hisense, TCL, Panasonic, Sharp, and RCA support Dolby Atmos and Dolby Vision.In Auto, Samsung Display is working with Dolby to pre tune its cutting edge OLED displays for autos to deliver Dolby Vision to more cars, Texas Instruments announced that it would support Dolby Atmos in its new family of chips for automakers, and Pioneer showcased how Dolby Atmos could be used in an aftermarket solution using a 4-channel speaker system.In PCs, ASUS, Dell, Lenovo, and Samsung announced a variety of new PCs, laptops, and monitors that support Dolby Vision and/or Dolby Atmos.Social Media app Xiaohongshu, which goes by the name RedNote in the U.S., now supports Dolby Vision.Amazon announced that the Fire TV Omni Mini-LED will support Dolby Atmos and Dolby Vision.All eight of the 2025 Grammy nominees for best new artist are available in Dolby Atmos, and seven out of eight Grammy nominees for Record of the Year and Album of the Year are available in Dolby Atmos.In 2024, over 80% of domestic box office and almost 70% of global box office came from Hollywood and local titles released in Dolby Atmos and Dolby Vision.

Dividend

Today, Dolby announced a cash dividend of $0.33 per share of Class A and Class B common stock, payable on February 19, 2025, to stockholders of record as of the close of business on February 11, 2025.

Financial Outlook

Dolby’s financial outlook relies, in part, on estimates of royalty-based revenue that take into consideration various factors that are subject to uncertainty, including consumer demand for electronic products. In addition, actual results could differ materially from the estimates Dolby is providing below due in part to uncertainty resulting from the macroeconomic effect of certain conditions, including supply chain constraints, international conflicts, geopolitical instability, and fluctuations in inflation and interest rates. The uncertainty resulting from these factors has greatly reduced its visibility into Dolby’s future outlook. To the extent possible, the estimates Dolby is providing for future periods reflect certain assumptions about the potential impact of certain of these items, based upon a consideration of currently available external and internal data and information. These assumptions are subject to risks and uncertainties. For more information, see “Forward-Looking Statements” in this press release for a description of certain risks that Dolby faces, and the section captioned “Risk Factors” in its Quarterly Report on Form 10-Q for the first quarter of fiscal 2025, to be filed on or around the date hereof.

Dolby is providing the following estimates for its second quarter of fiscal 2025:

Total revenue is estimated to range from $355 million to $385 million.Licensing revenue is estimated to range from $330 million to $360 million. Gross margins are anticipated to be approximately 89% on a GAAP basis and approximately 91% on a non-GAAP basis.Operating expenses are anticipated to range from $230 million to $240 million on a GAAP basis and from $190 million to $200 million on a non-GAAP basis.Effective tax rate is anticipated to be around 20.5% on a GAAP basis and around 18.5% on a non-GAAP basis.Diluted earnings per share is anticipated to range from $0.77 to $0.92 on a GAAP basis and from $1.19 to $1.34 on a non-GAAP basis.

Dolby is providing the following estimates for the full year of fiscal 2025:

Total revenue is expected to range from $1.33 billion to $1.39 billion.Licensing revenue is estimated to range from $1.22 billion to $1.28 billion. Gross margins are anticipated to be approximately 87% on a GAAP basis and approximately 90% on a non-GAAP basis.Operating expenses are anticipated to range from $915 million to $925 million on a GAAP basis and from $765 million to $775 million on a non-GAAP basis.Dolby expects operating margins to be roughly 20% on a GAAP basis and to be roughly 33% on a non-GAAP basis.Diluted earnings per share is anticipated to range from $2.39 to $2.54 on a GAAP basis and from $3.99 to $4.14 on a non-GAAP basis.

Conference Call Information

Members of Dolby management will lead a conference call open to all interested parties to discuss first quarter fiscal 2025 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Wednesday, January 29, 2025. Access to the teleconference will be available at http://investor.dolby.com or by dialing 1-800-210-2212 (+1-646-960-0390 for international callers) and entering confirmation code 5587811.

A replay of the call will be available from 5:00 p.m. PT (8:00 p.m. ET) on Wednesday, January 29, 2025, until 8:59 p.m. PT (11:59 p.m. ET) on Wednesday, February 5, 2025 by dialing 1-800-770-2030 (+1-647-362-9199 for international callers) and entering the confirmation code 5587811. An archived version of the teleconference will also be available on the Dolby website, http://investor.dolby.com.

Non-GAAP Financial Information

To supplement Dolby’s financial statements presented on a GAAP basis, Dolby management uses, and Dolby provides to investors, certain non-GAAP financial measures as an additional tool to evaluate Dolby’s operating results in a manner that focuses on what Dolby’s management believes to be its ongoing business operations and performance. We believe these non-GAAP financial measures are also helpful to investors in enabling comparability of operating performance between periods and among peer companies. Additionally, Dolby’s management regularly uses our supplemental non-GAAP financial measures to make operating decisions, for planning and forecasting purposes and determining bonus payouts. Specifically, Dolby excludes the following as adjustments from one or more of its non-GAAP financial measures:

Stock-based compensation expense: Stock-based compensation, unlike cash-based compensation, utilizes subjective assumptions in the methodologies used to value the various stock-based award types that Dolby grants. These assumptions may differ from those used by other companies. To facilitate more meaningful comparisons between its underlying operating results and those of other companies, Dolby excludes stock-based compensation expense.

Amortization of acquisition-related intangibles: Dolby amortizes intangible assets acquired in connection with business combinations. These intangible assets consist of patents and technology, customer relationships, and other intangibles. Dolby records amortization charges relating to these intangible assets in its GAAP financial statements, and Dolby views these charges as items arising from pre-acquisition activities that are determined by the timing and valuation of its acquisitions. As these amortization charges do not directly correlate to its operations during any particular period, Dolby excludes these charges to facilitate an evaluation of its current operating performance and comparisons to its past operating results. In addition, while amortization expense of acquisition-related intangible assets is excluded from Non-GAAP Net Income, the revenue generated from those assets is not excluded.

Restructuring charges or credits: Restructuring charges are costs associated with restructuring plans and primarily relate to costs associated with exit or disposal activities, employee severance benefits, and asset impairments. Dolby excludes restructuring costs, including any adjustments to charges recorded in prior periods (which may be credits), as Dolby believes that these costs are not representative of its normal operating activities and therefore, excluding these amounts enables a more effective comparison of its past operating performance and to that of other companies.

Income tax adjustments: The income tax effects of the aforementioned non-GAAP adjustments do not directly correlate to its operating performance so Dolby believes that excluding such income tax effects provides a more meaningful view of its underlying operating results to management and investors.

Using the aforementioned adjustments, Dolby provides various non-GAAP financial measures including, but not limited to: non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating margin, and non-GAAP effective tax rate. Dolby’s management believes it is useful for itself and investors to review both GAAP and non-GAAP measures to assess the performance of Dolby’s business, including as a means to evaluate period-to-period comparisons. Dolby’s management does not itself, nor does it suggest that investors should, consider non-GAAP financial measures in isolation from, superior to, or as a substitute for, financial information prepared in accordance with GAAP. Whenever Dolby uses non-GAAP financial measures, it provides a reconciliation of the non-GAAP financial measures to the most closely applicable GAAP financial measures. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as detailed above and below. Investors are also encouraged to review Dolby’s GAAP financial statements as reported in its US Securities and Exchange Commission (SEC) filings. A reconciliation between GAAP and non-GAAP financial measures is provided at the end of this press release and on the Dolby investor relations website, http://investor.dolby.com.

Forward-Looking Statements

Certain statements in this press release and in our earnings calls, including, but not limited to, expected financial results for the second quarter of fiscal 2025 and full year fiscal 2025, Dolby’s ability to expand existing business, navigate challenging periods, pursue its long-term growth opportunities, and advance its other long-term objectives are “forward-looking statements” that inherently involve substantial risks and uncertainties. These forward-looking statements are based on management’s current expectations, and as a result of certain risks and uncertainties, actual results may differ materially from those provided. The following important factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: the potential impacts of economic conditions on Dolby’s business operations, financial results, and financial position (including the impact to Dolby partners and disruption of the supply chain and delays in shipments of consumer products; the level at which Dolby technologies are incorporated into products and the consumer demand for such products; delays in the development and release of new products or services that contain Dolby technologies; delays in royalty reporting or delinquent payment by partners or licensees; lengthening sales cycles; the impact to the overall cinema market including adverse impact to Dolby’s revenue recognized on box-office sales and demand for cinema products and services; and macroeconomic conditions that affect discretionary spending and access to products that contain Dolby technologies); risks associated with geopolitical issues and international conflicts; risks associated with trends in the markets in which Dolby operates, including the broadcast, mobile, consumer electronics, PC, and other markets; the loss of, or reduction in sales by, a key customer, partner, or licensee; pricing pressures; risks relating to changing trends in the way that content is distributed and consumed; risks relating to conducting business internationally, including trade restrictions and changes in diplomatic or trade relationships; risks relating to maintaining patent coverage; the timing of Dolby’s receipt of royalty reports and payments from its licensees, including recoveries; changes in tax regulations; timing of revenue recognition under licensing agreements and other contractual arrangements; Dolby’s ability to develop, maintain, and strengthen relationships with industry participants; Dolby’s ability to develop and deliver innovative products and technologies in response to new and growing markets; competitive risks; risks associated with conducting business in countries that have historically limited recognition and enforcement of intellectual property and contractual rights; risks associated with the health of the motion picture and cinema industries generally; Dolby’s ability to increase its revenue streams and to expand its business generally, and to continue to expand its business beyond its current technology offerings; risks associated with acquiring and successfully integrating businesses or technologies; and other risks detailed in Dolby’s SEC filings and reports, including the risks identified under the section captioned “Risk Factors” in its Quarterly Report on Form 10-Q filed on or around the date hereof. Dolby may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements. Forward-looking statements are based upon information available to us as of the date of such statements, and while Dolby believes such information forms a reasonable basis for such statements, such information may be limited or incomplete. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Except as required by law, Dolby disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

About Dolby Laboratories

Dolby Laboratories (NYSE: DLB) is based in San Francisco, California with offices around the globe. From movies and TV shows, to apps, music, sports and gaming, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide. Dolby partners with artists, storytellers, developers, and businesses to revolutionize entertainment and communications with Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby.io.

Dolby, Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby.io, and the double-D symbol are among the registered and unregistered trademarks of Dolby Laboratories in the United States and/or other countries. Other trademarks remain the property of their respective owners.

DOLBY LABORATORIES, INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts; unaudited)

Fiscal Quarter Ended

December 27,
2024

December 29,
2023

Revenue:

   Licensing

$                330,479

$                293,767

   Products and services

26,520

21,807

Total revenue

356,999

315,574

Cost of revenue:

   Cost of licensing

21,110

15,736

   Cost of products and services

19,664

16,324

Total cost of revenue

40,774

32,060

Gross profit

316,225

283,514

Operating expenses:

   Research and development

66,638

67,033

   Sales and marketing

94,399

79,003

   General and administrative

70,092

65,166

   Restructuring charges

5,216

6,091

Total operating expenses

236,345

217,293

Operating income

79,880

66,221

Other income/(expense):

   Interest income/(expense), net

2,646

9,187

   Other income, net

3,525

5,425

Total other income

6,171

14,612

Income before income taxes

86,051

80,833

Provision for income taxes

(17,981)

(13,252)

Net income including noncontrolling interest

68,070

67,581

Less: net income attributable to noncontrolling interest

(248)

(600)

Net income attributable to Dolby Laboratories, Inc.

$                  67,822

$                  66,981

Net income per share:

   Basic

$                      0.71

$                      0.70

   Diluted

$                      0.70

$                      0.69

Weighted-average shares outstanding:

   Basic

95,615

95,376

      Diluted

97,147

97,439

 

DOLBY LABORATORIES, INC.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands; unaudited)

December 27,
2024

September 27,
2024

ASSETS

Current assets:

Cash and cash equivalents

$                520,821

$                482,047

Restricted cash

90,836

95,705

Accounts receivable, net

339,304

315,465

Contract assets, net

220,892

197,478

Inventories, net

31,833

33,728

Prepaid expenses and other current assets

82,113

69,994

Total current assets

1,285,799

1,194,417

Long-term investments

86,304

89,267

Property, plant, and equipment, net

476,113

479,109

Operating lease right-of-use assets

36,972

39,046

Goodwill and intangible assets, net

941,661

967,722

Deferred taxes

227,021

219,758

Other non-current assets

104,732

120,609

Total assets

$             3,158,602

$             3,109,928

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$                  11,550

$                  17,380

Accrued liabilities

360,915

347,529

Income taxes payable

20,875

9,045

Contract liabilities

37,111

31,644

Operating lease liabilities

11,426

12,238

Total current liabilities

441,877

417,836

Non-current contract liabilities

32,481

34,593

Non-current operating lease liabilities

33,019

34,754

Other non-current liabilities

134,197

135,852

Total liabilities

641,574

623,035

Stockholders’ equity:

Class A common stock

55

53

Class B common stock

40

41

Retained earnings

2,543,413

2,496,255

Accumulated other comprehensive loss

(35,542)

(19,187)

Total stockholders’ equity – Dolby Laboratories, Inc.

2,507,966

2,477,162

Noncontrolling interest

9,062

9,731

Total stockholders’ equity

2,517,028

2,486,893

Total liabilities and stockholders’ equity

$             3,158,602

$             3,109,928

 

DOLBY LABORATORIES, INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands; unaudited)

Fiscal Quarter Ended

December 27,
2024

December 29,
2023

Operating activities:

Net income including noncontrolling interest

$                  68,070

$                  67,581

Adjustments to reconcile net income to net cash provided by operating activities:

   Depreciation and amortization

22,362

17,872

   Stock-based compensation

36,070

31,894

   Amortization of operating lease right-of-use assets

2,835

3,088

   Amortization of premium on investments

(895)

   Provision for/(benefit from) credit losses

730

(2,101)

   Deferred income taxes

(7,307)

(5,397)

   Other non-cash items affecting net income

(3,059)

(1,745)

   Changes in operating assets and liabilities:

   Accounts receivable, net

(24,647)

(28,935)

   Contract assets, net

(23,416)

(35,400)

   Inventories

1,340

(9,297)

   Operating lease right-of-use assets

(2,487)

570

   Prepaid expenses and other assets

16,867

5,866

   Accounts payable and accrued liabilities

4,804

(31,993)

   Income taxes, net

15,305

6,184

   Contract liabilities

3,691

(1,116)

   Operating lease liabilities

(798)

(4,264)

   Other non-current liabilities

(3,581)

(3,503)

Net cash provided by operating activities

106,779

8,409

Investing activities:

Purchases of marketable securities

(35,753)

Proceeds from sales of marketable securities

1,226

Proceeds from maturities of marketable securities

41,259

Purchases of property, plant, and equipment

(6,779)

(6,099)

Business combinations, net of cash and restricted cash acquired, and other related payments

(1,362)

Net cash provided by/(used in) investing activities

(8,141)

633

Financing activities:

Proceeds from issuance of common stock

22,157

18,301

Repurchase of common stock

(15,000)

(80,002)

Payment of cash dividend

(31,548)

(28,552)

Distributions to noncontrolling interest

(740)

(1,047)

Shares repurchased for tax withholdings on vesting of restricted stock

(32,440)

(34,562)

Equity issued in connection with business combination

722

Net cash used in financing activities

(57,571)

(125,140)

Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash

(7,162)

6,790

Net increase/(decrease) in cash, cash equivalents, and restricted cash

33,905

(109,308)

Cash, cash equivalents, and restricted cash at beginning of period

577,752

817,966

Cash, cash equivalents, and restricted cash at end of period

$                611,657

$                708,658

 

Licensing Revenue by Market

(unaudited)

The following table presents the composition of our licensing revenue and percentage of total licensing revenue for all periods presented (in thousands, except percentage amounts):

Fiscal Quarter Ended

Market

December 27, 2024

December 29, 2023

Broadcast

$            115,762

35 %

$            112,416

38 %

Mobile

61,524

19 %

35,287

12 %

CE

49,457

15 %

53,220

18 %

PC

31,256

9 %

29,679

10 %

Other

72,480

22 %

63,165

22 %

Total licensing revenue

$            330,479

100 %

$            293,767

100 %

 

GAAP to Non-GAAP Reconciliations

(unaudited)

The following tables present Dolby’s GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the first quarters of fiscal 2025 and fiscal 2024:

Net income:

Fiscal Quarter Ended

(in thousands)

December 27,
2024

December 29,
2023

GAAP net income attributable to Dolby Laboratories, Inc.

$             67,822

$             66,981

Stock-based compensation (1)

36,070

31,894

Amortization of acquisition-related intangibles (2)

10,647

3,124

Restructuring charges

5,216

6,091

Income tax adjustments

(8,886)

(9,450)

Non-GAAP net income attributable to Dolby Laboratories, Inc.

$            110,869

$             98,640

(1) Stock-based compensation included in above line items:

   Cost of products and services

$                  487

$                  410

   Research and development

10,984

10,106

   Sales and marketing

12,645

10,481

   General and administrative

11,954

10,897

(2) Amortization of acquisition-related intangibles included in above line items:

   Cost of licensing

$               6,704

$                    62

   Cost of products and services

834

534

   Sales and marketing

754

656

   General and administrative

1,872

1,872

   Other income, net

483

Diluted earnings per share:

Fiscal Quarter Ended

December 27,
2024

December 29,
2023

GAAP diluted earnings per share

$                 0.70

$                 0.69

Stock-based compensation

0.37

0.33

Amortization of acquisition-related intangibles

0.11

0.03

Restructuring charges

0.05

0.06

Income tax adjustments

(0.09)

(0.10)

Non-GAAP diluted earnings per share

$                 1.14

$                 1.01

Weighted-average shares outstanding – diluted (in thousands)

97,147

97,439

 

The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial measures for the second quarter of fiscal 2025 and full year fiscal 2025 included in this release:

Gross margin:

Q2 2025

Fiscal 2025

GAAP gross margin

89.0 %

87.0 %

Stock-based compensation

0.1 %

0.1 %

Amortization of acquisition-related intangibles

1.9 %

2.9 %

Non-GAAP gross margin

91.0 %

90.0 %

Operating expenses (in millions):

Q2 2025

Fiscal 2025

GAAP operating expenses (low – high end of range)

$230 – $240

$915 – $925

Stock-based compensation

(34)

(131)

Amortization of acquisition-related intangibles

(3)

(9)

Restructuring charges

(3)

(10)

Non-GAAP operating expenses (low – high end of range)

$190 – $200

$765 – $775

Operating margin:

Fiscal 2025

GAAP operating margin

20% +/-

Stock-based compensation

10 %

Amortization of acquisition-related intangibles

3 %

Non-GAAP operating margin

33% +/-

Effective tax rate:

Q2 2025

GAAP effective tax rate

20.5 %

Stock-based compensation (low – high end of range)

(2%) – 0%

Amortization of acquisition-related intangibles (low – high end of range)

(1%) – 0%

Non-GAAP effective tax rate

18.5 %

Diluted earnings per share:

Q2 2025

Fiscal 2025

Low

High

Low

High

GAAP diluted earnings per share (low – high end of range)

$                 0.77

$              0.92

$                 2.39

$              2.54

Stock-based compensation

0.34

0.34

1.36

1.36

Amortization of acquisition-related intangibles

0.12

0.12

0.42

0.42

Restructuring charges

0.03

0.03

0.10

0.10

Income tax adjustments

(0.07)

(0.07)

(0.28)

(0.28)

Non-GAAP diluted earnings per share (low – high end of range)

$                 1.19

$              1.34

$                 3.99

$              4.14

Weighted-average shares outstanding – diluted (in thousands)

97,400

97,400

97,500

97,500

Investor Contact:
Peter Goldmacher
415-254-7415
peter.goldmacher@dolby.com 

Media Contact:
media@dolby.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/dolby-laboratories-reports-first-quarter-2025-financial-results-302363766.html

SOURCE Dolby Laboratories, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Solidion Technology Enters into Binding Strategic Patent Monetization Agreement with Hilco Global

Published

on

By

Company intends to monetize its foundational patent portfolio in the global $150 billion battery market

DALLAS, April 20, 2026 /CNW/ — Solidion Technology Inc. (“Solidion” or the “Company”) (Nasdaq: STI), an advanced battery technology solutions provider, announced that it has entered into a binding agreement with the IP Services Practice of Hilco Global (a subsidiary of Orix Company) to monetize its foundational energy portfolio and enforce its patent rights. Hilco has analyzed the Solidion patent portfolio to identify high value assets and the patent data suggest that a significant number of global companies will likely require a license to the Solidion portfolio.  In the energy storage segment in particular, virtually all the major players in the industry have technology that overlaps with the Solidion portfolio and the same appears to be true in semiconductors, consumer electronics and aerospace.

The value of Solidion’s portfolio could exceed $750 million.

Jaymes Winters, Chief Executive Officer of Solidion Technology, stated:

“The entire energy storage ecosystem has repetitiously utilized several of Solidion’s foundational patents to monetize their business models at a level rarely seen before. These are not just mom and pop startups, most of them are worldly known household names and industry leaders in not just EV battery storage, but other sectors such as semiconductors, aircraft and automotive manufacturing and cutting edge materials. The value of Solidion’s portfolio could exceed $750 million.”

Karl Maersch, head of the Patent Analysis & Monetization Group at Hilco IP Services, stated:

“Solidion’s portfolio covers various aspects of graphene and battery technology and it has applicability across multiple industry segments and includes companies that compete with Solidion and companies in adjacent technology segments.  In our view, the portfolio shows significant indicia of value and we are excited to partner with Solidion to help the company extract revenue from its portfolio.”

About Solidion Technology, Inc.

Headquartered in Dallas, Texas with pilot production facilities in Dayton, Ohio, Solidion’s (NASDAQ: STI) core business includes manufacturing of  battery materials and components, as well as development and production of next-generation batteries for energy storage systems, including including UPS systems serving the artificial intelligence (AI) data center market and electric vehicles for ground, aerospace, and sea transportation. Solidion holds a portfolio of over 345 patents, covering innovations such as high-capacity, silane gas free and graphene-enabled silicon anodes, biomass-based graphite, advanced lithium-sulfur and lithium-metal technologies.

For more information, please visit www.solidiontech.com or contact Investor Relations.

About Hilco Global

Hilco Global, a subsidiary of ORIX Corporation USA, is a diversified financial services company that delivers integrated professional services and capital solutions that help clients maximize value and drive performance across the retail, commercial and industrial, real estate, manufacturing, brand and intellectual property sectors, and more. Hilco Global provides a range of customized solutions to healthy, stressed, and distressed companies to resolve complex situations and enhance long-term enterprise value. Hilco Global works to deliver the best possible result by aligning interests with clients and providing strategic advice and, in many instances, the capital required to complete the deal. Hilco Global is based in Northbrook, Illinois and has more than 810 professionals operating on four continents.

Visit www.hilcoglobal.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc., (NASDAQ: STI) (the “Company,” “Solidion,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/solidion-technology-enters-into-binding-strategic-patent-monetization-agreement-with-hilco-global-302746839.html

SOURCE Solidion Technology, Inc.

Continue Reading

Technology

Following Pivotal Trial, FDA Set to Review First-of-a-Kind VR Autism Therapy

Published

on

By

WASHINGTON, April 20, 2026 /PRNewswire/ — Floreo, a developer of virtual reality (VR)-based therapeutic technologies, today announced the submission of a De Novo request to the U.S. Food and Drug Administration (FDA) for FloreoRx, its software-based product being evaluated for use in supporting skill development in individuals with Autism Spectrum Disorder. FloreoRx is an investigational device and has not yet been cleared or approved by the FDA.

In 2023, Floreo became the first VR autism technology to receive the FDA’s Breakthrough Device Designation, a program designed to expedite the development and review of technologies that may provide more effective treatment for serious conditions.

For many families and clinicians, access to consistent, high-quality autism therapy remains a persistent challenge. If authorized, FloreoRx could become one of the first FDA-authorized therapeutic devices intended to address core social communication challenges associated with Autism Spectrum Disorder. Using a VR headset and FloreoRx, behavioral therapists deliver structured experiences that enable users to safely develop and practice social communication skills through real-world scenarios and interactions.

The submission is supported by data from Floreo’s pivotal trial which utilized FloreoRx within Applied Behavioral Analysis (ABA) autism therapy evaluated against an active VR sham control. The study was 100% monitored and among the largest prospective, multi-site randomized controlled trials of a VR-based intervention conducted in children with autism.

The pivotal trial was conducted in partnership with Cortica Healthcare (Cortica) across 18 clinical sites nationwide, leveraging Cortica’s gold-standard integrated autism care model. Additionally, MCRA served as CRO and Highland BioMed provided strategic regulatory assistance with the preparation of the De Novo submission.

The trial focused on core social communication challenges associated with Autism Spectrum Disorder, assessed using the Autism Impact Measure (AIM). At clinically interpretable thresholds of improvement, participants receiving Floreo treatment demonstrated higher responder rates than those in the VR control group (e.g., 45.6% vs. 23.3%), with statistically significant differences between groups. These results were supported by consistent improvements across clinician-rated and functional measures.

Importantly, this trial also reflects the scale and operational capacity required to generate meaningful results in real-world care settings. Cortica enrolled 125 patients and coordinated more than 150 behavioral technician VR coaches and 15 blinded assessors across all sites involved in the study over a 15-month period, spanning both blinded therapy delivery and crossover.

“The clinical research continues to validate what clinicians and families are seeing every day: immersive VR can meaningfully support skill development for autistic learners,” said Vijay Ravindran, founder and CEO of Floreo. “Three things stand out in the trial: 1) That Floreo could achieve statistically significant results with a dosage of 18 minutes per week over 12 weeks, 2) That Floreo performed better as the severity of symptoms increased, and 3) that improvements continued to strengthen after 60 days.”

Clinical Highlights Include:

Social Skills: Clinician-administered CARS-2 evaluations showed a statistically significant LSMean change of -4.5 for the Floreo group versus -2.2 for the control (p = .0182).Subgroup Analysis (Highest-Burden Baseline): Participants in the highest-burden tertile at baseline demonstrated a 72% responder rate compared to 30% in the control group (p=0.009).Post-Treatment Observation: Improvements observed in AIM scores for the FloreoRx group at the 12-week end-of-treatment mark were sustained at the 60-day follow-up evaluation.High Skill Mastery: A majority of participants (95.1%) mastered one or more new skills by the end of treatment, as measured by the Assessment of Functional Living Skills.Family Quality of Life: Caregiver-reported CFQL-2 reports on family quality of life showed a between groups difference that was statistically significant for the Floreo group versus the control of 0.152 (p = 0.032).Crossover Findings: Participants who initially received the VR control demonstrated improvements after transitioning to Floreo treatment, supporting the consistency of the observed treatment effect.Safety Profile: No serious adverse events were reported in the study, and observed adverse events were generally mild and transient.High Engagement and Satisfaction Across Stakeholders: High levels of satisfaction were reported across clinicians and caregivers, including clinician-reported enjoyment of VR (98%) and willingness to use it as a treatment tool (88%), as well as parent-reported child enjoyment (93%) and interest in using VR as part of therapy (86%).

If authorized, Floreo intends to make FloreoRx available as an adjunct to existing therapeutic approaches, with the goal of expanding access to structured, skills-based interventions for the approximately 3% of children in the United States diagnosed with Autism Spectrum Disorder, where access to consistent, high-quality therapy remains a significant challenge.

Floreo currently offers a commercially available VR platform designed for general wellness and skills development that does not make medical or therapeutic claims. FloreoRx is a separate investigational product under FDA review.

About Floreo
Floreo’s vision is a world that is open and accessible for every neurodiverse person. Through immersive virtual reality experiences, Floreo creates safe, engaging environments where learners can build skills and tools they can apply in their everyday lives. Floreo’s virtual reality platform teaches social, behavioral, communication, and life skills for individuals with Autism Spectrum Disorder and other neurodiverse conditions. For more information, please visit floreovr.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/following-pivotal-trial-fda-set-to-review-first-of-a-kind-vr-autism-therapy-302746375.html

SOURCE Floreo

Continue Reading

Technology

Hyperscale Data Accelerates Michigan Operations Capabilities for AI Data Center and Robotics Hub

Published

on

By

Company Advances Facility Reconfiguration and Robotics Capabilities, with Plans to Hire 500+ Employees Over Three Years

LAS VEGAS, April 20, 2026 /PRNewswire/ — Hyperscale Data, Inc. (NYSE American: GPUS), an artificial intelligence (“AI”) data center company anchored by Bitcoin (“Hyperscale Data” or the “Company”), today announced that it is accelerating the enhancement of its Michigan operations into a combined AI data center and robotics hub, following its recently executed agreement with AGIBOT PTE. LTD. (“AGIBOT”), a developer of intelligent robotics technology.

The Company is advancing the reconfiguration of key sections of its existing building on its 34.5-acre campus to support AI infrastructure, robotics deployment, and large-scale data generation. Hyperscale Data currently operates approximately 30 megawatts (“MW”) of power capacity at the site, and the Company believes there is potential to expand to over 300 MW over time.

Building an Integrated AI and Robotics Platform

Hyperscale Data is enhancing its Michigan operations to combine high-performance computing infrastructure with robotics capabilities. Sections of the existing building are being re-imagined to support robotics assembly, testing, and deployment alongside AI model training and validation.

As part of this initiative, the Company is initially dedicating more than 100,000 square feet within its existing 617,000 square foot facility to AI and robotics operations. Within this footprint, the Company plans to:

Develop robotics assembly and testing capabilities;Build real-world environments for data collection and system validation; andIntegrate compute infrastructure with robotics-driven data generation.

Data generated through these activities is expected to be commercialized and utilized within U.S. markets, supporting domestic AI development and deployment.

Supporting Next-Generation AI Development

Hyperscale Data believes that the next phase of AI will increasingly depend on real-world data and physical system training in addition to traditional digital datasets.

The Michigan campus is being developed to support:

Machine-generated data from robotics operating in real environments;Human (egocentric) data capture for contextual learning;Testing and validation of robotic systems; and  Training workflows for advanced AI models.

Workforce Expansion and Regional Impact

Hyperscale Data expects to hire more than 500 employees over the next three years to support its Michigan operations. Anticipated roles include robotics engineers, AI data specialists, infrastructure personnel, and operations staff.

The Company expects to pursue opportunities to support frontier AI developers, those advancing large-scale models and next-generation robotics systems, and high-performance computing platforms as demand for these capabilities evolves.

Investor Webcast

Hyperscale Data invites investors and the public to join its previously announced Tuesday webcast, where management will provide additional details on the Michigan enhancement, robotics strategy, and AI infrastructure plans. To register for the webcast, please visit here.

The webcast will feature:

William B. Horne, Chief Executive Officer; andMilton “Todd” Ault III, Executive Chairman.

Executive Commentary

William B. Horne, Chief Executive Officer of Hyperscale Data, stated:

“We are enhancing our Michigan operations into a scaled AI and robotics platform that supports both high-performance compute and real-world data generation. This next phase of development positions us to support evolving AI workloads while creating high-quality jobs in the region.”

Milton “Todd” Ault III, Executive Chairman of Hyperscale Data, added:

“This initiative builds on our existing infrastructure and expands it into a more comprehensive AI ecosystem. By combining compute, robotics, and data generation in a single environment, we are developing infrastructure aligned with where artificial intelligence is heading.”

For more information on Hyperscale Data and its subsidiaries, Hyperscale Data recommends that stockholders, investors and any other interested parties read Hyperscale Data’s public filings and press releases available under the Investor Relations section at hyperscaledata.com or available at www.sec.gov.

About Hyperscale Data, Inc.

Through its wholly owned subsidiary Sentinum, Inc., Hyperscale Data owns and operates a data center at which it mines digital assets and offers colocation and hosting services for the emerging AI ecosystems and other industries. Hyperscale Data’s other wholly owned subsidiary, Ault Capital Group, Inc. (“ACG”), is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact.

Hyperscale Data currently expects the divestiture of ACG (the “Divestiture”) to occur in the second quarter of 2027. Upon the occurrence of the Divestiture, the Company would be an owner and operator of data centers to support high-performance computing services, as well as a holder of the digital assets. Until the Divestiture occurs, the Company will continue to provide, through ACG and its wholly and majority-owned subsidiaries and strategic investments, mission-critical products that support a diverse range of industries, including an AI software platform, equipment rental services, defense/aerospace, industrial, automotive, medical/biopharma and hotel operations. In addition, ACG is actively engaged in private credit and structured finance through a licensed lending subsidiary. Hyperscale Data’s headquarters are located at 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141.

On December 23, 2024, the Company issued one million (1,000,000) shares of a newly designated Series F Exchangeable Preferred Stock (the “Series F Preferred Stock”) to all common stockholders and holders of the Series C Preferred Stock on an as-converted basis. The Divestiture will occur through the voluntary exchange of the Series F Preferred Stock for shares of Class A Common Stock and Class B Common Stock of ACG (collectively, the “ACG Shares”). The Company reminds its stockholders that only those holders of the Series F Preferred Stock who agree to surrender such shares, and do not properly withdraw such surrender, in the exchange offer through which the Divestiture will occur, will be entitled to receive the ACG Shares and consequently be shareholders of ACG upon the occurrence of the Divestiture.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties.

Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company’s website at hyperscaledata.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hyperscale-data-accelerates-michigan-operations-capabilities-for-ai-data-center-and-robotics-hub-302746909.html

SOURCE Hyperscale Data Inc.

Continue Reading

Trending